Table 3.
A summary of various cancer antigens expressed by different cancers.
| Cancer | Antigen |
|---|---|
| Ovarian cancer | B7H690, natural killer group 2 member D (NKG2D)91, human epidermal growth factor receptor 2 (HER2)92, alpha folate receptor (alpha FR)93, TNF-related apoptosis-inducing ligand (TRAIL) receptor 1 (TRAIL-receptor 1)94, adhesion molecule L1-CAM (L1-CAM) (CD171)95 |
| Glioblastoma | Interleukin-13Ra2 (IL13Ra2)96, AC13397, type III variant of the epidermal growth factor (EGFR)98, erythropoietin-producing hepatocellular A2 (EphA2)99, |
| Prostate cancer | Prostate-specific membrane antigen (PSMA)100 |
| Pancreatic cancer | Prostate stem cell antigen (PSCA)101, carcinoembryonic antigen (CEA)102 |
| Neuroblastoma | Disialoganglioside 2 (GD2), L1-CAM (CD171)95 |
| Breast carcinoma | MUC-1103, chondroitin sulfate proteoglycan-4 (CSPG4)104 |
| Lung cancer | EphA2105 |
| Malignant pleural mesotheliomas | Mesothelin106 |
| Colon cancer | TRAIL-receptor 1107 |
| Hepatocellular carcinoma | Glypican-3 (GPC3)108 |
| Renal cell carcinoma | Carbonic anhydrase IX (CAIX)57,109 |